Saudi Arabia, Turkey, and Egypt Immunohematology Market, By Product Type (Immunohematology Analyzer and Immunohematology Reagent), Technology (Microplates, Gel Cards, Erythrocyte-Magnetized Technology (EMT), Polymerase Chain Reaction and Others), Application (Antibody Screening and Blood Typing), End User (Blood Banks, Hospitals, Diagnostic and Reference Laboratories, Academic and Research Institutes), Distribution Channel (Direct Sales, Retail Sales and Third Party Distribution) - Industry Trends and Forecast to 2030.
Saudi Arabia, Turkey and Egypt Immunohematology Market Analysis and Insights
The Saudi Arabia, Turkey, and Egypt immunohematology market is expected to grow in the forecast year due to an increase in the number of product launches with innovation and technological advancement to meet the needs of the market is expected to foster the market's growth. The key market players are increasingly interested in employing new technologies to attract the end-user attention. The usage of blood typing and antibody screening kits or instruments are rapidly growing and offers a tremendous opportunity in this sector. Consequently, the demand for immunohematology products are increasing due to the rising prevalence of trauma incidences and immunohematology disorders worldwide. However, the lack of skilled professionals to carry out hematology testing may hamper the growth of the market.
Saudi Arabia, Turkey and Egypt immunohematology market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 3.8%, 4.2% and 3.0% in the forecast period of 2023 to 2030, respectively for Turkey, Saudi Arabia and Egypt.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015 – 2020) |
|
Quantitative Units |
Revenue in USD Million |
|
Segments Covered |
Product Type (Immunohematology Analyzer and Immunohematology Reagent), Technology (Microplates, Gel Cards, Erythrocyte-Magnetized Technology (EMT), Polymerase Chain Reaction and Others), Application (Antibody Screening and Blood Typing), End User (Blood Banks, Hospitals, Diagnostic and Reference Laboratories, Academic and Research Institutes), Distribution Channel (Direct Sales, Retail Sales and Third Party Distribution) |
|
Countries Covered |
Saudi Arabia, Turkey and Egypt |
|
Market Players Covered |
Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Ortho Clinical Diagnostics (a Subsidiary of QuidelOrtho Corporation) (Egypt), Merck KGaA. (Germany), Beckman Coulter, Inc. (a Subsidiary of Danaher Corporation) (U.S.), Abbott (U.S.), Bio-Rad Laboratories, Inc. (U.S.), and HORIBA (Japan) among others.
|
Market Definition
A subfield of medicine called immunohematology studies how the immune system interacts with blood, specifically identifying blood cell antigens and associated antibodies. It covers the theories and clinical methods involved in contemporary transfusion therapy. Blood transfusion attempts to save human lives have been documented for several centuries.
RBCs contain more than 230 different types of antigens, which can be divided into two main categories based on their chemical makeup: carbohydrates and polypeptides. If the genes are known and found on nearby loci, they are categorized in blood group systems, and if the genes responsible for their formation have not yet been identified, they are categorized in blood group collections. Specific genes that are inherited from parents are responsible for the RBC antigen formation. Because an ABO mismatch can be lethal, the ABO blood group system, which was the first to be identified at the turn of the 20th century, is still regarded as the most significant antigenic system. However, the High cost of hematology instruments, reagents and kits and standards for the approval and commercialization of products is expected to restrain the market growth.
Saudi Arabia, Turkey and Egypt Immunohematology Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Increasing demand for blood and blood products
Most patients who have a major surgical procedure will have a blood transfusion to replace any blood loss during their surgery. Blood transfusions are used for patients who have experienced serious injuries from car crashes or natural disasters. Individuals with an illness that causes anemia, such as leukemia or kidney disease, will often be the recipients of blood transfusions.
Thus, the increasing demand for blood and blood products is expected to accelerate the growth of the immunohematology market significantly in the nearby future.
- Technological advancements for the development of new products
Since the discovery of the ABO system, numerous important innovations have contributed to a continuous, rapid evolution in the diagnostic methods for in vitro measurements of the antigen-antibody reaction, allowing a significant improvement in the compatibility between blood from donors and recipients.
Apart from the introduction of ABO typing, these methods include the determination of Rh type and phenotype, the direct and indirect antiglobulin tests, cross-matching and consequent identification of antigens and antibodies of clinical relevance, the use of low ionic strength additives and enzyme treatments, the development of monoclonal reagents and solid-phase and microcolumn platforms for performing the pre-transfusion tests.
Thus, technological advancements for the development of new products is expected to drive market growth.
Opportunities
-
Rising awareness about blood donation
Blood donations can yield a variety of blood products, including red cells, platelets and plasma. You may be most familiar with the typical whole blood donation drive seen at workplaces, schools and community events, but there are a few other ways to help give more life through the Red Cross. For cancer patients, blood transfusions can act as a resource to implement platelets back into the body after heavy treatments such as chemo or radiation therapy.
Therefore, a rise in awareness about blood donation is further expected to create a lot of opportunities for the market to grow.
-
Rising cases of blood cancer
Blood cancer is a type of cancer that affects the blood cells. Leukaemia, lymphoma and myeloma are some of the most common types of blood cancer. There are also types called MPNs and MDS. Blood cancer is caused by changes (mutations) in the DNA within blood cells. This causes the blood cells to start behaving abnormally. Thus, rising cases of blood cancer is expected to act as an opportunity for market growth in the coming years.
Restraints/Challenges
- High Cost of blood testing and transfusion
The transfusion is a burden for both the hospital management systems and the country's economy. To accurately calculate and manage this economic burden is important for sustainable healthcare services. Allogeneic blood transfusion causes variable costs according to different applications in treatment expenditures. It imposes an economic burden to purchase, test and prepare the component suitable for transfusion, deliver blood components to relevant clinics, apply to the recipient, monitor and treat transfusion-induced reactions, dispose of it as medical waste, and file all mandatory information.
Hence, the high cost of blood testing and transfusion, which is further restraining the growth of the market to an extent.
- Risk of transfusion- transmitted infections
Transfusion-transmitted infections (TTIs) are infections resulting from the introduction of a pathogen into a person through blood transfusion. A wide variety of organisms, including bacteria, viruses, prions, and parasites, can be transmitted through blood transfusions.
Bacterial contamination of blood products, especially in platelets stored at room temperature, is the most common infectious risk of blood transfusion, occurring in approximately 1 in every 2,000-2,500 platelet transfusions. Transfusion–transmitted sepsis, while less common, can cause severe illness and death. Improved donor screening and improved methods of collection, handling, and storing of blood products have decreased bacterial contamination in recent years.
For instance,
- In December 2022, according to the information provided by National Center for Biotechnology Information (NCBI), Hepatitis B virus, HCV, and syphilis carry the greatest risk of transfusion-transmittable infection (TTI) in Saudi Arabia. Including HBsAg screening is a necessary precautionary measure to maintain blood safety
Hence the risk of transfusion transmitted infections will act as a challenge to the market.
Recent Development
- In August 2022, Bio-Rad Laboratories, Inc. announced that the company acquired Scope Fluidics, S.A., a Warsaw, Poland-based developer of cutting-edge technology solutions for the medical diagnostic and healthcare markets, has agreed to sell all of Curiosity Diagnostics, Sp. Z. o. o.'s outstanding shares to Bio-Rad Laboratories, Inc. for a total consideration of up to $170 million, consisting of roughly $100 million in cash and up to $70 million in potential future milestone payments. A sample-to-answer, rapid diagnostics PCR system is being developed by Curiosity Diagnostics, a late-stage, pre-commercial platform firm, for the molecular diagnostics market. This prompted the company to grow its clientele.
- In July 2022, Beckman Coulter, Inc. announced a partnership with Scopio in order to hasten the deployment of their most recent platforms for peripheral blood smears. In order to completely replace manual microscopy, Scopio's technology uses Full-Field imaging and AI decision support while offering laboratory workers and doctors a genuine workflow boost. The Scopio systems streamline lab operations and enhance workflow in a distributed network with easy-to-use remote viewing. No longer must slides be sent between locations; high quality full-field images may now be transmitted in real time across a secure hospital network. This has aided the corporation in using modern technology to grow its operations.
Saudi Arabia, Turkey, and Egypt Immunohematology Market Scope
Saudi Arabia, Turkey, and Egypt immunohematology market is segmented into five notable segments such as product type, technology, application, end user and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product Type
- Immunohematology Analyzer
- Immunohematology Reagent
On the basis of product type, Saudi Arabia, Turkey, and Egypt immunohematology market is segmented into immunohematology analyzer and immunohematology reagent.
Technology
- Microplates
- Gel Cards
- Erythrocyte Magnetized Technology (EMT)
- Polymerase Chain Reaction
- Others
On the basis of technology, the Saudi Arabia, Turkey, and Egypt immunohematology market is segmented into microplates, gel cards, erythrocyte magnetized technology (EMT), polymerase chain reaction and others.
Application
- Antibody Screening
- Blood Typing
On the basis of application, the Saudi Arabia, Turkey, and Egypt immunohematology market is segmented into antibody screening and blood typing.
End User
- Blood banks
- Hospitals
- Diagnostics and Reference Laboratories
- Academic and Research Institutes
On the basis of end user, the Saudi Arabia, Turkey, and Egypt immunohematology market is segmented into blood banks, hospitals, diagnostics and reference laboratories, and academic and research institutes.
Distribution Channel
- Direct Sales
- Retail Sales
- Third Party Distribution
On the basis of distribution channel, the Saudi Arabia, Turkey, and Egypt immunohematology market is segmented into direct sales, retail sales and third party distribution.
Saudi Arabia, Turkey and Egypt Immunohematology Market Regional Analysis/Insights
The immunohematology market is analyzed, and market size insights and trends are provided by country, product type, technology, application, end user and distribution channel.
Competitive Landscape and Saudi Arabia, Turkey and Egypt Immunohematology Market Share Analysis
The immunohematology market competitive landscape provides details of the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the company's focus on the ataxia market.
Some of the key players operating in Saudi Arabia, Turkey, and Egypt immunohematology market are Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., Abbott, F. Hoffmann-La Roche Ltd, Ortho Clinical Diagnostics, Boule, Merck KGaA, Beckman Coulter, Inc., Abbott, Bio-Rad Laboratories, Inc., HORIBA and among others.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.2 DRUG TREATMENT RATE BY MATURED MARKETS
5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE
5.4 KEY PRICING STRATEGIES
6 REGULATORY GUIDELINES FOR IMMUNOHEMATOLOGY
6.1 REGULATIONS IN SAUDI ARABIA
6.2 REGULATIONS IN TURKEY
6.3 REGULATIONS IN EGYPT
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING DEMAND FOR BLOOD AND BLOOD PRODUCTS
7.1.2 TECHNOLOGICAL ADVANCEMENTS FOR THE DEVELOPMENT OF NEW PRODUCTS
7.1.3 INCREASING INCIDENCE OF TRAUMA AND IMMUNOHEMATOLOGICAL DISORDERS
7.2 RESTRAINTS
7.2.1 HIGH COST OF BLOOD TESTING AND TRANSFUSION
7.2.2 STRINGENT REGULATIONS FOR IMMUNOHEMATOLOGY TESTING IN SAUDI ARABIA, TURKEY, AND EGYPT
7.3 OPPORTUNITIES
7.3.1 RISING AWARENESS ABOUT BLOOD DONATION
7.3.2 RISING CASES OF BLOOD CANCER
7.4 CHALLENGES
7.4.1 RISK OF TRANSFUSION-TRANSMITTED INFECTIONS
7.4.2 LACK OF SKILLED PERSONNEL TO CARRY OUT IMMUNOHEMATOLOGY TESTING.
8 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 IMMUNOHEMATOLOGY ANALYZER
8.3 IMMUNOHEMATOLOGY REAGENT
9 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 MICROPLATES
9.3 GEL CARDS
9.4 POLYMERASE CHAIN REACTION
9.5 ERYHTROCYTE-MAGNETIZED TECHNOLOGY (EMT)
9.6 OTHERS
10 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 BLOOD TYPING
10.3 ANTIBODY SCREENING
11 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET, BY END USER
11.1 OVERVIEW
11.2 BLOOD BANKS
11.3 HOSPITALS
11.4 DIAGNOSTIC AND REFERENCE LABORATORIES
11.5 ACADEMIC AND RESEARCH INSTITUTES
12 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT SALES
12.3 THIRD PARTY DISTRIBUTION
12.4 RETAIL SALES
13 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: TURKEY
13.2 COMPANY SHARE ANALYSIS: SAUDI ARABIA
13.3 COMPANY SHARE ANALYSIS: EGYPT
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 ABBOTT
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENT
15.2 ORTHO CLINICAL DIAGNOSTICS
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENTS
15.3 SIEMENS HEALTHINEERS AG
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENTS
15.4 BECKMAN COULTER, INC.
15.4.1 COMPANY SNAPSHOT
15.4.2 REVNUE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENT
15.5 HORIBA
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENTS
15.6 BIO RAD LABORATORIES, INC.
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENTS
15.7 IMMUCOR, INC.
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENTS
15.8 MERCK KGAA
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENTS
15.9 THERMO FISCHER SCIENTIFIC INC.
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
List of Figure
FIGURE 1 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET: SEGMENTATION
FIGURE 2 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET: DATA TRIANGULATION
FIGURE 3 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET: DROC ANALYSIS
FIGURE 4 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET: DBMR MARKET POSITION GRID
FIGURE 9 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET: SEGMENTATION
FIGURE 11 INCREASING DEMAND FOR BLOOD AND BLOOD PRODUCTS AND TECHNOLOGICAL ADVANCEMENTS FOR THE DEVELOPMENT OF NEW PRODUCTS IS EXPECTED TO DRIVE THE GROWTH OF THE SAUDI ARABIA IMMUNOHEMATOLOGY MARKET FROM 2023 TO 2030
FIGURE 12 INCREASING DEMAND FOR BLOOD AND BLOOD PRODUCTS AND TECHNOLOGICAL ADVANCEMENTS FOR THE DEVELOPMENT OF NEW PRODUCTS IS EXPECTED TO DRIVE THE GROWTH OF THE TURKEY IMMUNOHEMATOLOGY MARKET FROM 2023 TO 2030
FIGURE 13 INCREASING DEMAND FOR BLOOD AND BLOOD PRODUCTS AND TECHNOLOGICAL ADVANCEMENTS FOR THE DEVELOPMENT OF NEW PRODUCTS IS EXPECTED TO DRIVE THE GROWTH OF THE EGYPT IMMUNOHEMATOLOGY MARKET FROM 2023 TO 2030
FIGURE 14 THE IMMUNOHEMATOLOGY ANALYZER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE SAUDI ARABIA IMMUNOHEMATOLOGY MARKET IN 2023 & 2030
FIGURE 15 THE IMMUNOHEMATOLOGY ANALYZER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE TURKEY IMMUNOHEMATOLOGY MARKET IN 2023 & 2030
FIGURE 16 THE IMMUNOHEMATOLOGY ANALYZER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EGYPT IMMUNOHEMATOLOGY MARKET IN 2023 & 2030
FIGURE 17 PATIENT FLOW DIAGRAM
FIGURE 18 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET
FIGURE 19 TURKEY IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, 2022
FIGURE 20 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, 2022
FIGURE 21 EGYPT IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, 2022
FIGURE 22 TURKEY IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 23 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 24 EGYPT IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 25 TURKEY IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 26 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 27 EGYPT IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 28 TURKEY IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 29 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 30 EGYPT IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 31 TURKEY IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, 2022
FIGURE 32 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, 2022
FIGURE 33 EGYPT IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, 2022
FIGURE 34 TURKEY IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 35 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 36 EGYPT IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 37 TURKEY IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 38 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 39 EGYPT IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 40 TURKEY IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 41 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 42 EGYPT IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 43 TURKEY IMMUNOHEMATOLOGY MARKET: BY APPLICATION, 2022
FIGURE 44 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY APPLICATION, 2022
FIGURE 45 EGYPT IMMUNOHEMATOLOGY MARKET: BY APPLICATION, 2022
FIGURE 46 TURKEY IMMUNOHEMATOLOGY MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 47 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 48 EGYPT IMMUNOHEMATOLOGY MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 49 TURKEY IMMUNOHEMATOLOGY MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 50 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 51 EGYPT IMMUNOHEMATOLOGY MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 52 TURKEY IMMUNOHEMATOLOGY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 53 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 54 EGYPT IMMUNOHEMATOLOGY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 55 TUKEY IMMUNOHEMATOLOGY MARKET: BY END USER, 2022
FIGURE 56 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY END USER, 2022
FIGURE 57 EGYPT IMMUNOHEMATOLOGY MARKET: BY END USER, 2022
FIGURE 58 TURKEY IMMUNOHEMATOLOGY MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 59 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 60 EGYPT IMMUNOHEMATOLOGY MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 61 TURKEY IMMUNOHEMATOLOGY MARKET: BY END USER, CAGR (2023-2030)
FIGURE 62 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY END USER, CAGR (2023-2030)
FIGURE 63 EGYPT IMMUNOHEMATOLOGY MARKET: BY END USER, CAGR (2023-2030)
FIGURE 64 TURKEY IMMUNOHEMATOLOGY MARKET: BY END USER, LIFELINE CURVE
FIGURE 65 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY END USER, LIFELINE CURVE
FIGURE 66 EGYPT IMMUNOHEMATOLOGY MARKET: BY END USER, LIFELINE CURVE
FIGURE 67 TURKEY IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 68 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 69 EGYPT IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 70 TURKEY IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 71 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 72 EGYPT IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 73 TURKEY IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 74 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 75 EGYPT IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 76 TURKEY IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 77 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 78 EGYPT IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 79 TURKEY IMMUNOHEMATOLOGY MARKET: COMPANY SHARE 2022 (%)
FIGURE 80 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: COMPANY SHARE 2022 (%)
FIGURE 81 EGYPT IMMUNOHEMATOLOGY MARKET: COMPANY SHARE 2022 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
